July 18, 2025European Journal of Heart Failure8 citationsOpen Access
Heart Failure Hospitalizations and Clinical Outcomes in Patients Undergoing Tricuspid Transcatheter Edge-To-Edge Repair: Insights from EuroTR
Ver artículo completo
PICO estructurado
Does a history of heart failure hospitalization affect clinical outcomes in patients undergoing T-TEER for symptomatic tricuspid regurgitation, and does T-TEER reduce subsequent HFH risk?
P
Población
1000 patients undergoing tricuspid transcatheter edge-to-edge repair (T-TEER) for symptomatic tricuspid regurgitation (TR) from the EuroTR registry.
I
Intervención
Tricuspid transcatheter edge-to-edge repair (T-TEER)
C
Comparador
Patients with no heart failure hospitalization (HFH) vs single HFH vs multiple HFH prior to T-TEER; also pre- vs post-T-TEER comparison
O
Resultado
All-cause mortality and combined endpoint of all-cause mortality or HFHhard clinical
In patients undergoing T-TEER for symptomatic TR, a history of heart failure hospitalization predicts worse mortality, but successful T-TEER significantly reduces subsequent HFH risk.
Resumen
AIMS: To assess the prevalence, prognostic significance, and predictors of heart failure hospitalization (HFH) before and after tricuspid transcatheter edge-to-edge repair (T-TEER) in a large real-world cohort of patients with tricuspid regurgitation (TR). METHODS AND RESULTS: Data from the European Registry of Transcatheter Repair for Tricuspid Regurgitation (EuroTR registry) were analysed. Among 1000 patients undergoing T-TEER for symptomatic TR, 361 (36.1%) had no HFH, 459 (45.9%) had one single HFH, and 180 (18.0%) had multiple HFH the year before T-TEER. Patients with any HFH had more severe heart failure compared with those without. Procedural success (residual TR ≤2) did not differ between patients with single, multiple, or no HFHs before T-TEER. Multivariable analysis showed that a history of HFH was associated with an increased mortality risk (adjusted hazard ratio HR 1.51, 95% confidence interval CI 1.11-2.06 for single vs. no HFH; adjusted HR 1.63, 95% CI 1.15-2.31 for multiple vs. no HFH), and a higher risk of the combined endpoint of all-cause mortality or HFH. HFH risk decreased by 72% in the 1 year following T-TEER compared to the previous year. Procedural success was the sole independent predictor for reducing HFHs. CONCLUSIONS: In the EuroTR cohort, a history of HFH was highly prevalent and associated with worse clinical outcomes. Among high-risk patients with symptomatic TR, T-TEER significantly lowered HFH risk, with residual TR grade ≤2 being the key predictor for reduced HFH incidence.